

## .Curriculum Vita



OCTOBER-2018

### Personal Background:

**First Name:** Peyman

**Family Name:** Eshghi

**Place of Birth:** Tehran, IR of Iran

**Nationality:** Iranian

**Marital Status:** Married

**Date of Birth:** 30/08/1964

**Gender:** Male

**Home Address:** \*\*\*\*\*

**Work Address:** Mofid Children Hospital, Shariati Aven., Tehran, IRAN, 15468-15514

**Work Website:** [www.pchd.sbmu.ac.ir](http://www.pchd.sbmu.ac.ir)

Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

**Tel:** +98 21 22265488, +98 21 22904536

**Tel(mobile) :** \*\*\*\*\*

**Tel-fax (office) :** +98 21 22265488, +98 21 22904536

**e-mail :** [p\\_eshghi@sbmu.ac.ir](mailto:p_eshghi@sbmu.ac.ir)

**Cc :** [[peshghi64@gmail.com](mailto:peshghi64@gmail.com)]

## Educational Background:

**1983-1990:** MD. , Tehran Medical University

**1990-1993:** Pediatric specialty, Children Medical Center, Tehran Medical University, Tehran, Iran

**1994-1997:** Pediatric Hematology & Oncology subspecialty, Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran

## Employment and Related Professional Activities ,Membership and Affiliation:

### **Current situation and positions:**

- 1) Prof. in pediatric Hematology & Oncology department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran :**May/2012-now**
- 2) **Founder and first Chair man of Iranian Society of Thrombosis and Hemostasis (IRSTH) since Jan-2016**
- 3) Head of pediatric Hematology & Oncology department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran : **May/2011-now**
- 4) Head attendant of Mofid Comprehensive Care Center for Children with Hemophilia: **2007-now**
- 5) **Research Deputy of “Pediatric Congenital Hematologic Disorders Research Center”:**  
**Aug/2012-now**
- 6) **Research Deputy of “Research Institute of Child Health”:** **April/20116-now**

- 7) Board Member of Pediatric Hematology & Oncology Sub-specialty discipline in MOH:  
**2007-now**
- 8) Board member of Iranian Pediatric Hematology & Oncology Society (**IPHOS**) :**2000-now**
- 9) Director of Strategic Planning Committee for Pediatric Hematology & Oncology of MOH.  
: **2007-now**
- 10) Member of hematologist counselors Committee in Deputy of health of MOH: **2005-now**
- 11) Member of Research committee of Iranian Blood Transfusion Organization: **2005-now**

 **Previous and other situations and positions:**

- 12) Associate Prof. in Pediatric Hematology & Oncology, department of Mofid Children Hospital, Shahid Beheshti Medical University, Tehran, Iran: **2007- 2012**
- 13) Assistant Prof. in pediatric Hematology & Oncology, department of Mofid Children Hospital, , Tehran, Iran: **2005-2007**
- 14) Assistant Prof. in pediatric Hematology & Oncology; Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran; **1997-2005 ]**
- 15) Counsellor to General Director of Iranian Blood Transfusion Organization: **2005-2010**
- 16) President of Ali Asghar Children hospital, Zahedan Medical University, Zahedan, Iran:  
**2000- 2004**
- 17) Head of committee for Establishment of prenatal diagnosis center in Sistan & Balouchestan province(as the 5<sup>th</sup> national PND center in IRAN) and clinical attendant of this center: **2002-2005**
- 18) Board member of Zahedan Medicine Council Organization: **2004-2006**
- 19) Editorial Board Member of Scientific Journal of Iranian Blood Transfusion Organization (BLOOD): **2007-now**

And:

- Member of many other Scientific and Executive committees in Medical Universities, and Iranian Blood Transfusion Organization , regional, national and international congresses in IRAN: **1997-now**

- Speaker and coordinator in national workshops, congresses and CME seminars around the country and abroad **1997-now**
- Referee of many national medical journals: **2000-now**

### **Official Appreciations and Awards for Employment and Related Professional Activities:**

#### **1- IRI Medicine Council Organization:**

- as the best Pediatric Hematologist and Oncologist in Iran: in **2005**

#### **2- Ministry of health and medicine education:**

- for Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2005**
- for Diligently cooperation with National Thalassemia Prevention Program; **2008**
- for presentation an article about Medical Documents and improvement in medical education **2000**

#### **3- Zahedan division of IRI Medicine Council Organization:**

- as the best physician in S&B Province: **2001**

#### **4- Zahedan Medical University:**

- for Establishment of prenatal diagnosis center in Sistan & Balouchestan province **2004**
- for especial respectability for patients and parents in Ali Asghar Children Hospital **2004**
- for successful educational efforts and obtaining the first national rank in resident training: **1999**
- for establishment of Rooming in service for mothers and neonates **1994**
- The best faculty member. **2001**

## Publications:

### **Book Authoring:**

- 1) **Comprehensive Management for Thalassemia in Iran** -2<sup>ND</sup> edition(in Persian); MOH publication: 2018
- 2) Therapeutic Algorithms Of Musculoskeletal Complications Of Hemophilia(in Persian); Nashre Adiban publication: 2010
- 3) **Lymphadenopathy in children** (in Persian): [Pediatric Infectious Disease Research Center, Mofid children Hospital]; Donya-ye Taghzieh publication: 2009
- 4) **Comprehensive Management for hemophilia in Iran** (in Persian); MOH publication: 2008
- 5) **Comprehensive Management for Thalassemia in Iran** (in Persian); MOH publication: 2006
- 6) **Comprehensive textbook of Thalassemia in IRAN** (in Persian) Baghiat-allah University publication: 2005
- 7) **Textbook of Pediatrics** (in Persian); Shahid Beheshti University publication: 2005

### **Published Articles in international journals:**

- 1) Nasrin Dehghan-Nayeri, Peyman Eshghi, Kouros Goudarzi Pour, Ahmad Gharehbaghian, A systematic review of proteomic biomarkers associated with risk stratification in pediatric acute lymphoblastic leukemia. *Journal of Paramedical Sciences (JPS)* Winter 2018 Vol 9, No1. ISSN 2008-4978
- 2) K. KAVAKLI, F. DEMARTIS, M. KARIMI, P. ESHGHI, D. NEME, H. CHAMBOST, L. SOMMER, M. ZAK and G. BENSON. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. *Haemophilia* (2017), 1-8.
- 3) Francesco Demartis, Angelika Batorova, Hervé Chambost, Peyman Eshghi, Mehran Karimi, Kaan Kavakli, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer Vestergaard, Gary Benson. Real-World Early Treatment with Room Temperature–

- Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses. *TH Open* 2017; 01(02): e130-e138, DOI: 10.1055/s-0037-1608943
- 4) Gholamreza Azizi ,Hassan Abolhassani ,Seyed Alireza Mahdaviani ,Zahra Chavoshzadeh,Peyman Eshghi ,Reza Yazdani ,Fatemeh Kiaee ,Mohammadreza Shaghghi ,Javad Mohammadi ,Nima Rezaei ,Lennart Hammarström ,Asghar AghamohammadiClinical, immunologic, molecular analyses and outcomes of iranian patients with LRBA deficiency: A longitudinal study.PAI, Volume28, Issue5,August 2017,Pages 478-484.
  - 5) **Leila Khanali Mojen, Maryam Rassouli,<sup>1</sup> Peyman Eshghi,<sup>1</sup> Ali Akbari Sari,<sup>2</sup> andMajideh Heravi Karimooi<sup>3</sup> · Palliative Care for Children with Cancer in the Middle East: A Comparative Study. *Indian J Palliat Care*. 2017 Oct-Dec; 23(4): 379–386. doi: [10.4103/IJPC.IJPC\_69\_17]**
  - 6) Marjan Aghvami<sup>‡</sup>,Ahmad Salimi<sup>‡</sup>,Peyman Eshghi,Mohammad H Zarei,Shabnam Farzaneh,Fatemeh Sattari,Afshin Zarghi,Jalal Pourahmad. Targeting the mitochondrial apoptosis pathway by a newly synthesized COX-2 inhibitor in pediatric ALL lymphocytes. *Future Medicinal Chemistry* .Published Online: 11 Oct 2018 <https://doi.org/10.4155/fmc-2018-0032>
  - 7) Marjan Aghvami, Peyman Eshghi, Mohammad Hadi Zarei, Hadi Arefi, Fatemeh Sattari, Afshin Zarghi and Jalal Pourahmad.Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes. *Iranian Journal of Pharmaceutical Research* (2018), 17 (4): 1476-1487
  - 8) **Sezaneh Haghpanah,Tahereh Zarei,Peyman Eshghi,Omidreza Zekavat,Mohammadeza Bordbar,Mahmood Hoormand,Mehran Karimi**. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. ***Annals of Hematology*.October 2018, Volume 97, Issue 10, pp 1919–1924**
  - 9) Hassan Abolghasemi, MD1, Yunes Panahi, PhD2\*, Minoos Ahmadinejad, MD3, Gholamreza Toogeh, MD4, Mehran Karimi, MD5, Aziz Eghbali, MD6, Nargess Bigom Mirbehbahani, MD7, Bighan Keikhaei Dehdezi, MD8, Zahra Badiiee, MD9, Hamid Hoorfar, MD10, Peyman Eshghi, MD1, Nader Maghsoudi, PhD11, Amirhossein Sahebkar, PhD12,13,14, Mohammad Gholami- Fesharaki, PhD15. Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. *Journal of Pharmacopuncture* 2018;21[2]:076-081
  - 10) Leila Khanali Mojen<sup>1</sup> , Maryam Rassouli<sup>1</sup> \*, Peyman Eshghi<sup>2</sup> , Kazem Zendedel<sup>3</sup> , Ali Akbari Sari<sup>4</sup> , Majideh Heravi Karimooi<sup>5</sup> , Mamak Tahmasebi<sup>3</sup> , Azam Shirin Abadi Farahani<sup>1</sup>. Pediatric Palliative Care in Iran: Applying Regionalization of Health Care Systems. *Asian Pac J Cancer Prev*, 19 (5), 1303-1311

11) Peyman Eshghi<sup>1\*</sup>, Ali Amin Asnafi<sup>2</sup>, Ahmadreza Shamshiri<sup>1</sup>, Samin Alavi<sup>1</sup>, Mohammad Molavi<sup>3</sup>, Ahmad Tamaddoni<sup>4</sup>, Bijan Keikhaie<sup>2</sup>, Majid Naderi<sup>5</sup>, Hamid Hoorfar<sup>6</sup>, Shahla Ansari<sup>7</sup>, Azita Azarkeivan<sup>8</sup>, Majid Arasteh<sup>9</sup>, Zahra Kourorian<sup>1</sup>. The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major. *IJBC* 2017; 9(3): 2-6

12) **Kourosh Goudarzipour, Parinaz Alizadeh, Hesameddin Hoseini Tavassol, Reyhaneh Kazemi, Peyman Eshghi, Saeed Mojtahedzadeh.** A Comparison Between MRIT<sup>2</sup> and NT-ProBNP in Early Detection of Heart Diseases in Thalassemia Major Patients: A Cross-Sectional Study. *Indian Journal of Hematology and Blood Transfusion*. December 2017, Volume 33, Issue 4, pp 541–544

13) [Karimi M<sup>1</sup>](#), [Eshghi P<sup>2</sup>](#), [Safarpour MM<sup>1</sup>](#), [Haghpanah S<sup>1</sup>](#), [Meshksar A<sup>1</sup>](#), [Zahedi Z<sup>1</sup>](#), [Habibpanah B<sup>2</sup>](#). Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran. *J Pediatr Hematol Oncol*. 2018 Jan 19. doi: 10.1097/MPH.0000000000001082. [Epub ahead of print]

14) **Peyman Eshghi**, MD1, Elham Sadeghi, MD1, S. Zahra Tara, MD1, Behnaz Habibpanah, BSc1, and Razieh Hantooshzadeh, MD. **Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B.** *Clinical and Applied Thrombosis/Hemostasis*. *Clin Appl Thromb Hemost*. (2017 Jan) ,1-8. 61:1076029616685429. doi: 10.1177/1076029616685429.

15) Nasrin Dehghan-Nayeri , Mostafa Rezaei-Tavirani<sup>1</sup> , Mir Davood Omrani , Ahmad Gharehbaghian ,Kourosh Goudarzi Pour, Peyman Eshghi. Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia. *J. Cell Commun. Signal*. DOI 10.1007/s12079-016-0357-3

16) **Dehghan-Nayeri N., Gharehbaghian A., Goudarzi Pour K., Eshghi P.** Over expression of the fatty acid synthase is a strong predictor of poor prognosis and contributes to glucocorticoid resistance in B-cell acute lymphoblastic leukemia. *WCRJ* 2016; 3 (3): e746.

17) Goudarzi Pour K, Malek F, Eshghi P. Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™). *Case Rep Hematol*. 2016;2016:1295092. doi: 10.1155/2016/1295092. Epub 2016 Jul 10.

18) Kourosh Goudarzipour MD, Peyman Eshghi MD, Zahra Tara MD, Abolfazl Afjeh MD, Farid Solat MD, Masoumeh Shiravi MD. Prevalence of microcytosis in cord blood samples and admitted neonates in Tehran, Iran . *Iran J Ped Hematol Oncol*. 2016, Vol6.No3, 166-171

19) Gharibnaseri Z1, Davari M2, Cheraghali A3, Eshghi P4, Ravanbod R5, Espandar R6, Hantooshzadeh R7. Health care resource utilization and cost of care for haemophilia A and B patients in Iran. *Transfus Apher Sci*. 2016 Feb;54(1):122-6.

- 20) Faranoush M1, Abolghasemi H2, Mahboudi F3, Toogeh G4, Karimi M5, Eshghi P6, Managhchi M4, Hoorfar H7, Dehdezi BK8, Mehrvar A9, Khoeyni B10, Vaziri B3, Kamyar K10, Heshmat R4, Baghaeipour MR11, Mirbehbahani NB12, Fayazfar R13, Ahmadinejad M14, Naderi M15. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor. Clin Appl Thromb Hemost. 2016 Mar;22(2):184-90
- 21) Mina Golestania, Peyman Eshghib, Abdol Majid Cheraghali\*, Hamid Reza Rasekhd,e, Jamshid Salamzadehe, Ali Imani. **Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran.** Iranian Journal of Pharmaceutical Sciences-2016 12 (2): 85-90
- 22) Mina Golestania, Peyman Eshghib\*, Hamid Reza Rasekhd, Abdol Majid Cheraghali, Jamshid Salamzadehc, Majid Naderie, Mohammad Reza Managhchif, Hamid Hoorfarg, Gholam Reza Toogehf, Ali Imanih, Mohammad Taghi Khodayarij, Behnaz Habibpanahb and Razieh Hantooshzadehj. **Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.** Iranian Journal of Pharmaceutical Research (2016), 15 (2): 669-677
- 23) Flora Peyvandi, M.D., Ph.D., Pier M. Mannucci, M.D., Isabella Garagiola, Ph.D., Amal El-Beshlawy, M.D., Mohsen Elalfy, M.D., Vijay Ramanan, M.D., **Peyman Eshghi, M.D.**, Suresh Hanagavadi, M.D., Ramabadran Varadarajan, M.D., Mehran Karimi, M.D., Mamta V. Manglani, M.D., Cecil Ross, M.D., Guy Young, M.D., Tulika Seth, M.D., Shashikant Apte, M.D., Dinesh M. Nayak, D.N.B., Elena Santagostino, M.D., Maria Elisa Mancuso, M.D., Adriana C. Sandoval Gonzalez, M.D., Johnny N. Mahlangu, M.Med., Santiago Bonanad Boix, M.D., Monica Cerqueira, M.D., Nadia P. Ewing, M.D., Christoph Male, M.D., Tarek Owaidah, F.R.C.P.A., Veronica Soto Arellano, M.D., Nathan L. Kobrinsky, M.D., Suvankar Majumdar, M.B., Ch.B., Rosario Perez Garrido, M.D., Anupam Sachdeva, M.D., Mindy Simpson, M.D., Mathew Thomas, M.D., Ezio Zanon, M.D., Bulent Antmen, M.D., Kaan Kavakli, M.D., Marilyn J. Manco-Johnson, M.D., Monica Martinez, M.D., Esperanza Marzouka, M.D., Maria G. Mazzucconi, A.P., Daniela Neme, M.D., Angeles Palomo Bravo, M.D., Rogelio Paredes Aguilera, M.D., Alessandra Prezotti, M.D., Klaus Schmitt, M.D., Brian M. Wicklund, M.D., Bulent Zulfikar, M.D., and Frits R. Rosendaal, M.D., Ph.D. **A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.** N Engl J Med 2016; 374:2054-2064
- 24) Gholamreza Toogeh; Hassan Abolghasemi; **Peyman Eshghi**; Mohammadreza Managhchi; Mohammadreza Shaverdi-niasari; Katayoun Karimi; Samin Roostaei; Neda Emran; Alireza



Abdollahi. Evaluation of Aryoseven Safety (recombinant activated factor VII) in patients with bleeding disorders (An observational post-marketing surveillance, study). *IJP Articles in Press*, Accepted Manuscript , Available Online from 11 May 2016

- 25) Gharibnaseri Z<sup>1</sup>, Davari M<sup>2</sup>, Cheraghali A<sup>3</sup>, **Eshghi P**<sup>4</sup>, Ravanbod R<sup>5</sup>, Espandar R<sup>6</sup>, Hantooshzadeh R<sup>7</sup>. **Health care resource utilization and cost of care for haemophilia A and B patients in Iran.** *Transfus Apher Sci.* 2016 Feb;54(1):122-6.
- 26) **Eshghi P**, Abolghasemi H, Malek F\*, Naderi M, Panahi Y, Habibpanah B, Fatohlahzadeh E, Gorji F. **A Prospective Crossover Triple-Blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto®) Versus Plasma Derived FVIII; A Pilot Study.** *IJBC* 2015; 7(4): 171-175
- 27) **Eshghi P** , Malek F , Madani F , Esfahani H . **Therapeutic Plasma Exchange in Pediatric Severe Immune Thrombocytopenia: A Case Report and Literature Review.** *IJBC* 2015; 7(3): 119-122
- 28) Faranoush M, Abolghasemi H, Toogeh G, Karimi M, **Eshghi P**, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M. **A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency.** *Clin Appl Thromb Hemost.* 2015 Nov;21(8):724-8. doi: 10.1177/1076029614522545. Epub 2014 Mar 19.
- 29) Akbar Dorgalaleh, Majid Naderi, Maryam Sadat Hosseini, Shaban Alizadeh, Soudabeh Hosseini, Shadi Tabibian, Peyman Eshghi: **Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature.** *Semin Thromb Hemost* 2015; 41(03): 323-329
- 30) Mina Golestani ; Peyman Eshghi ; Hamid Reza Rasekh ; Abdol Majid Cheraghali ; Jamshid Salamzadeh ; Ali Imani . Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors. *Iran Red Crescent Med J.* 2014 December; 16(12): e24551
- 31) Kajbafzadeh AM, Sabetkish S, Tourchi A, Amirizadeh N, Afshar K, Abolghasemi H, Elmi A, Talab SS, **Eshghi P**, Mohseni MJ. The application of tissue-engineered preputial matrix and fibrin sealant for urethral reconstruction in rabbit model. *Int Urol Nephrol.* 2014 Mar 12. [Epub ahead of print]
- 32) Naderi, Dorgalaleh Majid, Tabibian Akbar, Shadi Eshghi, **Eshghi P**, Taregh Alizadeh, Shaban. Association Between Val34Leu Polymorphism and Risk of Umbilical Cord Bleeding in Severe Congenital Coagulation Factor XIII Deficiency in Southeast of Iran. *Gene Cell Tissue.* 2014; 1(1): e 18360.

- 33) **Eshghi P.**, Jenabzadeh Alireza, Habibpanah Behnaz. Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital. *Iranian Journal of Blood & Cancer*. 2014; 6(3); 127-131.
- 34) Naderi Majid, Zarei Tahereh, Haghpanah Sezaneh, **Eshghi P**, Miri-Moghaddam Ebrahim, Karimi Mehran. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. April 2014, Volume 93, [Issue 4](#), pp 693-697
- 35) Naderi M, Dorgalaleh, Tabibian S, Alizadeh Sh, **Eshghi P**, Hosseini S. Effect of Consanguineous Marriages on the High Prevalence of Factor XIII Deficiency in Southeast of Iran. *Iranian journal of public health* 2013;
- 36) Goudarzi Pour K, **Eshghi P**, Aghakhani R, Askari Reza A, Nejat Mahmud P. Neuroblastoma Associated with Bilateral Ptosis: Report of a Rare Condition. *Iranian Journal of Blood and Cancer*. 2013; 6(1): 55-57.
- 37) **Eshghi P**, Jenabzade A, Habibpanah B. A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. *Hematology*. 2013 Oct 26. [Epub ahead of print]
- 38) The comparison of side effects and iron excretion in urine by two brands of deferoxamine( Desfonak® and Desferal® ) in major Thalassemia patients.
- 39) Alavi Samin, Malek Fatima, **Eshghi P**, Arzhangian Hossein. Autologous Platelet-Rich Plasma for Healing of an Oncologic Dehiscid Wound. *APSP J Case Rep* 2013; 4(3):44
- 40)** Dorgalaleh A , Naderi M, **Eshghi P**, Tabibian shadi. Clinical manifestations of rare bleeding disorders in South East of Iran Hemophilia. 2013; 19(2):PO 382
- 41) Naderi M, Dorgalaleh A, Tabibian Sh, Alizadeh Sh, **Eshghi P**, Solaimani G. Current understanding in diagnosis and management of factor XIII deficiency. *Iran J Ped Hematol Oncol*. 2013;3(4):164-72.
- 42) Ziaee Seyyed Amir Mohsen, Reza Sarhangnejad, Hassan Abolghasemi, **Eshghi P**, Mohammad Hadi Radfar, Ali Ahanian, Mehdi Kardoust Parizi, Nasser Amirizadeh, Akbar Nouralizadeh. Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study *Urology journal (impact factor: 0.58)*. 01/2013; 10(3):999-1003.

- 43) Alzobie A, Belhani M, **Eshghi P**, Kupesiz AO, Ozelo M, Pompa MT, Potgieter J, Smith M. Establishing a harmonized haemophilia registry for countries with developing health care systems. *Haemophilia*. 2013 Apr 17. doi: 10.1111/hae.12147. Epub 2013 Apr 17
- 44) Naderi M, **Eshghi P**, Cohan N, Haghpanah S, Karimi M. Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. *Haemophilia*. 2013 Mar 19. doi: 10.1111/hae.12112. [Epub ahead of print]
- 45) Alizadeh Z, Fazlollahi MR, Houshmand M, Maddah M, Chavoshzadeh Z, Hamidieh AA, Shamsian BS, **Eshghi P**, Bolandghamat Pour S, Sadaaie Jahromi H, Mansouri M, Movahedi M, Nayebpour M, Pourpak Z, Moin M. Different pattern of gene mutations in Iranian patients with severe congenital neutropenia (including 2 new mutations). *Iran J Allergy Asthma Immunol*. 2013 Mar;12(1):86-92. doi: 012.01/ijaai.869213.
- 46) Salehi Tahmineh, Fazlollahi Mohammad Reza, Maddah Marzieh, Nayebpour Mohsen, Tabatabaei, Yazdi, Mojtaba Alizadeh, Zahra, **Eshghi P**, Chavoshzadeh Zahra Movahedi, Masoud Hamidieh, Amirali Cheraghi, Taher Pourpak, Zahra Moin, Mostafa. Prevention and Control Of Infections In Patients With Severe Congenital Neutropenia; A Follow Up Study. *Iranian Journal Of Allergy, Asthma And Immunology (Ijaai)*. 2012; 11(1): 51-56.
- 47) Naderi M **Eshghi P**, Saneei Moghaddam E, Alizadeh S, Dorgalaleh A, Younesi MR, Khateb ZK. Safety of human blood products in rare bleeding disorders in southeast of Iran. *Haemophilia*. 2012 Dec 6. doi: 10.1111/hae.12068. [Epub ahead of print]
- 48) K. Salem, **Eshghi P**. Dental health and oral health-related quality of life in children with congenital bleeding disorders. *Haemophilia* (2012), 1–6
- 49) Naderi M, **Eshghi P**, Cohan N, Miri-Moghaddam E, Yaghmaee M, Karimi M. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. *Haemophilia*. 2012 Sep;18(5):773-776. Epub 2012 Mar 28.
- 50) Cheraghali Abdol Majid, **Eshghi P**. Cost Assessment of Implementation of Immune Tolerance Induction in Iran. *Value in Health Regional Issues*. 1 ( 2 0 1 2 ) 5 4 – 5 8
- 51) M. Karimi, A. Vafafar, S. Haghpanah, M. payandeh, **Eshghi P**, H. Hoofar, A. Afrasiabi, J. Gerdabi, R. Ardeshiri, M. Menegatti– and F. Peyvandi. Efficacy of

- prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. *Haemophilia* (2012), 18, 211–215
- 52) **Eshghi P**, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran *Clin Appl Thromb Hemost*. 2011 Dec 6. [Epub ahead of print]
- 53) Alizadeh Z, Fazlollahi MR, **Eshghi P**, Hamidieh AA, Ghadami M, Pourpak Z. Iran Two Cases of Syndromic Neutropenia with a Report of Novel Mutation in G6PC3. *J Allergy Asthma Immunol*. 2011 Sep;10(3):227-30
- 54) **Eshghi P**, Farahmandinia Z. , Molavi M., Naderi M. , Jafroodi M. , Hoorfar H., Davari K., Azarkeivan A. , Keikhaie B. , Ansari S. , Arasteh M. : Efficacy and safety of Iranian made Deferasirox (osveral®) in Iranian major Thalassemic Patients with transfusional iron overload : A One year Prospective Multicentric Open-Label Non-Comparative study. *Daru*, 2011, Vol. 19, No.3, 240-248
- 55) A.M. Cheraghali, **Eshghi P**, H. Abolghasemi .Social consequences of infected haemophilia cases in the Islamic Republic of Iran. *EMHJ*, 2011, Vol. 17 ,No. 6 ,.552-556
- 56) Miri-Moghaddam E., Zadeh-Vakili A., Rouhani Z., Naderi M., **Eshghi P**, Khazaei A. Feizabad6. Molecular basis and prenatal diagnosis of  $\beta$ -thalassemia among Balouch population in Iran. *Prenat Diagn* (2011)
- 57) Alireza Foroutan, Fariba Beigzadeh, Mohammad Jafar Ghaempanah, **Eshghi P**, Naser Amirizadeh, PhD, Hamed Sianati, MD, Pooria Foroutan, MD. Efficacy of Autologous Fibrin Glue for Primary Pterygium Surgery with Conjunctival Autograft. *Iranian Journal of Ophthalmology* 2011;23(1):39-47
- 58) Kajbafzadeh AM, Abolghasemi H, **Eshghi P**, Alizadeh F, Elmi A, Shafaattalab S, Dianat S, Amirizadeh N, Mohseni MJ. Single-donor fibrin sealant for repair of urethrocutaneous fistulae following multiple hypospadias and epispadias repairs. *J Pediatr Urol*. 2010 Jul 14. [Epub ahead of print]
- 59) Eghbali Aziz, **Eshghi P**, Malek F, Abdollahpour Hengameh., Rezaei Nima. HAX1 mutation in an infant with severe congenital neutropenia. *The Turkish Journal of Pediatrics* 2010; 52: 81-84
- 60) **Eshghi P**, Mitra Mahdavi-Mazdeh, Mehran Karimi, Mohammad Aghighi. Haemophilia in the developing countries: the Iranian experience. *Arch Med Sci* 2010; 6, 1: 83-89

- 61) **Eshghi P**, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. *Haemophilia*. 2010 Mar;16(2):383-5.
- 62) Zadeh-Vakili A, **Eshghi P** Detection of a rare mutation in an Iranian family: codons 37/38/39 (7 bp deletion). *Hemoglobin*. 2009;33(6):523-7.
- 63) **Eshghi P**, Rashidi A, Zadeh-Vakili A, Miri-Moghaddam E. Hematological phenotype of the IVS-I-5 (G > C) beta-thalassemia mutation and assessment of Iran's national screening criteria. *Hemoglobin*. 2008;32(5):440-5.
- 64) **Eshghi P.**, Zadeh-Vakili A, Rashidi A, Miri-Moghaddam E. An unusually frequent beta-thalassemia mutation in an Iranian Province. *Hemoglobin*. 2008;32(4):387-92.
- 65) Trinh CH, Sh Elsayed W, **Eshghi P**, Miri-Moghaddam E, Zadeh-Vakili A, Markham AF, Anwar R. Molecular analysis of sixteen unrelated factor XIII A deficient families from south-east of Iran. *Br J Haematol*. 2008 Mar;140(5):581-4.
- 66) Sharifi-Mood B, **Eshghi P**, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. *Saudi Med J*. 2007 Oct;28(10):1516-9.
- 67) Abolghasemi H, Amid A, Zeinali S, Radfar MH, **Eshghi P**, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H. Thalassemia in Iran: epidemiology, prevention, and management. *J Pediatr Hematol Oncol*. 2007 Apr;29(4):233-8
- 68) **Eshghi P**, Alavi S, Ghavami S, Rashidi A.. Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors. *J Pediatr Hematol Oncol*. 2007 Jan;29(1):5-8.
- 69) Ashena Zahra, Alavi Samin, Arzanian Mohammad Taghi., **Eshghi P**, Nail involvement in Langerhans cell Histiocytosis, *Pediatric Hematology and Oncology*, 24:45–51, 2007
- 70) Sharifi-Mood B, Smail Sanei-Moghaddam, Salehi M, **Eshghi P**, Soheila Khosravi and Manijeh Khalili. Viral Infection among Patients with Hemophilia in the Southeast of Iran, *Journal of Medical Sciences* 2006; 6(2): 225-228,
- 71) Karimi M. **Eshghi P.**, Unusual Lymphoblastic Leukemia/Lymphoma in Eastern Iran ,*Indian Journal of Pediatrics*, 2006; 73

72) **Eshghi P**, Abolghasemi Hassan, Esmail Sanei-Moghaddam, , Anwar Rashida, Jazebi Mohammad , Amid Ali, Fereydoun A. Ala, MD, FRCP, FRCPath ,, Factor XIII deficiency in southeast Iran, Haemophilia (2004), 10, 470–472

 **Published Articles in Iranian Journals:**

**In Persian:**

- 1) Arzanian M.T., Shamsian B.Sh., Eshghi P., Kajiyazdi M., Alavi S., Nazari Sh., Goudarzipour K. The clinical application of port A Cath in the hematology-oncology patients Sci J Iran Blood Transfus Organ 2015; 12(1): 85-99
- 2) Factor XIII deficiency in Sistan and Baluchistan province. Naderi M, Imani M, Alizadeh Sh, Dorgalaleh A, Tabibian Sh, **Eshghi P**, Sanei Moghaddam E, Mirimoghaddam E, Journal of Iranian Blood transfusion Organization Research Center 01/2013
- 3) Miri-Moghaddam E., Eshghi P., Sanei Moghaddam E., Hashemi SM. Prevalence of hemoglobinopathies in Sistan and Balouchistan province in the southeast of Iran. Sci J Iran Blood Transfus Organ 2013; 9(4): 406-413
- 4) Azarkeivan A, Arjangyan MH, Hajibeigi B, Afradi H, Aghaeepour M, Razjoo F, Sharifi SH, **Eshghi P**. Evaluation and Comparison of Washed RBCs by Closed and Open systems. Scientific Journal of Zanjan University; 1390; 19(75):66-76.
- 5) **Eshghi P**, Amin Asnafi A. Cerebral venous thrombosis in a child with Acute Lymphoblastic Leukemia and G20210A mutation of prothrombin gene during treatment. Sci J Iran Blood Transfus Org. 2011; 8(2): 143-148
- 6) Zahedpanah M, Azarkeivan A, Hajibeigi B, Ahmadinezhad M, **Eshghi P**, Tabatabaiee M.R. 1, Maghsudlu M. Coagulation inhibitors in Thalassemia. Sci J Iran Blood Transfus Org. 2010; 7(2): 78-84
- 7) Eshghi P.1,2(MD), Cheraghali A.M.1,3(PhD); Legal, social, and economic consequences of transfusion transmitted infections in Iran and in the world. **The Scientific Journal of Iranian Blood Transfusion Organization Research Center. Volume 6, Number 4 (Spring 2009)**
- 8) Noori N, **Eshghi P**, Shahramian I. Evaluation the effectiveness of combined iron chelation with deferipron and desferoxamine on the cardiac function in major beta

- thalassemic children in Zahedan,1383-1384. Tabib-e Shargh. Winter 88.No.11,Vol4.:35-40
- 9) Hashemi Teir A.1(MS), Amirizadeh N.1(PhD), **Eshghi P.**, Abolghasemi H.1,3(MD),Amani M.1(MS), Jabari A.1(BS), Ranjbaran R.1(MS), Mohammadi M.H.1(MS),Habibi Roudkenar M.1(PhD), Ali Balazadeh A. **Study of *in vitro* properties of fibrin sealant prepare from single donor plasma** 4(BS. *Sci J Iran Blood Transfus Org* 2009; 6(3): 181-189
- 10) Noori N, **Eshghi P.** Evaluation the effectiveness of captopril on the left heart function in major beta thalassemic children in Zahedan, 1381-1382. Scientific Medical Journal. Winter 2008; 6(4 (55)):492-498.
- 11) Shahriari HA, MD; Ghasemzadeh F, MD; **P. Eshghi**, MD; Masoomian B, MD. **Ocular Side Effects of Desferal<sup>®</sup> in Patients with <sup>®</sup>Thalassemia.** Bina J Ophthalmol 2006; 11 (4): 519-523
- 12) **Eshghi Peyman**, Aliakbarian M, Taheribojd M.A, Davoudabadi H.**Classification of Arthropathies in Severe hemophilia type A, referred to Zahedan in 2003.** Medical Journal Of Mashad University of Medical Sciences, No.91, Vol49, Spring 2006
- 13) Abolghsemi H, **Eshghi Peyman**, Rahiminejad M.S, Hatami S. Evaluation and Cost-Effectiveness Analysis Of Prevention Program Of **Major Thalassemic** in in **Sistan and Baluchestan province** and Fars Province, HAKIM Winter. 2006; 8():85-14.
- 14) **Eshghi Peyman**, Rahimi M, Razaghi A;**Evaluation of effect of Family practice Consultation on Knowledge, Attitude and Practice of Major Thalassemic`s Parents in the Prevention Program in Southeast IRAN,** Scientific Medical Journal of Ahwaz University of Medical Science , No.49 , Vol5, No2, Summer 2006.
- 15) **Eshghi Peyman** MD , Abolghasemi H. MD. , Sanei moghadam E. MD. , et al. , **Prevalence of factor XIII deficiency and abnormal clot solubility test in Sistan and Baluchestan province,** Hakim Research Journal , Vol.6 ,No.4 , Winter 2004
- 16) **Eshghi Peyman** MD, Razlansari Ali Akbar MD. , Roodbari Masood PHD . , **Prevalence of Impaired Oral Glucose Tolerance Test in Major Thalassemic Patients with and without Hepatitis C Virus Infection in Zahedan in 2001,** Scientific Medical Journal of

Ahwaz University of Medical Science , No.38 ,December 2003.

- 17) **Eshghi Peyman MD. , Sanei moghadam E. MD., Mirmasoudi M. MD, Evaluation of Alloimmunization in major B.thalassemic patients in zahedan in 2001**, Journal of Mazandaran University of Medical Sciences , Vol.13 No.40 , Autumn 2003.
- 18) Miri-Moghadam E., Naroinejad.Mehrnaz , **Eshghi Peyman**, et al. **Molecular basis and Prenatal diagnosis of thalassemia in southeast Iran** . Journal Of Mazandaran University OF Medical Sciences, Fall 2003; 13():36-42.

**In English:**

- 1) Neda Ashayeri, Elham Sadeghi, Sara Sadeghi, Peyman Eshghi, Samin Alavi · Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta-thalassemia Major in Iran; A Non-randomized Controlled Trial. *IJBC* 2016; 8(4): 103-107
- 2) **Eshghi P** , Jenabzadeh A , Habibpanah B . **Hemorrhage Treatment Report of Patients Suffering from Glanzmann's Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children's Hospital.** *IJBC* 2014;6(3): 127-131
- 3)
- 4) **Eshghi P** , Khanali L , Abed-Saeedi J , Farahani H , Abdolah Gorgi F , Habib-Panah B , Tehrani Tarighat S , Alavi S ,Taslimi S · The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children. *IJBC* 2013;2: 57-60
- 5) **Peyman Eshghi**, Nader Cohan, Majid Naderi, Mehran Karimi. Factor XIII deficiency: a review of literature. *IJBC* 2012;2: 85-91
  
- 6) Eshghi P. Moradveisi B. **Frequency of Decreased Bone Mineral Density and Its Risk Factors during Childhood among Iranian Hemophilia Patients.** Iranian Journal Of Blood And Cancer 2011;4(1):
- 7) Peyman Eshghi,Kourosh Goudarzipour,Hoorieh Davoudabadi Farahani, Roxana Aghakhani Intra articular Injection of Rifampin in Iranian Children with Hemophilic Arthropathy. Iranian Journal of Blood and Cancer,Volume 3, Number 2. Winter 2011



- 8) Peyman Eshghi , Kourosh Goudarzi Pour and Roxana Aghakhani.  
Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis. Iranian Journal of Blood and Cancer, Volume 1, Number 4 (2009)
- 9) Aziz Eghbali, MD; Peyman Eshghi, MD; Fatemeh Malek, MD and Nima Rezaei, MD, PhD. Cardiac and Renal Malformations in a Patient with Sepsis and Severe Congenital Neutropenia. Iran J Pediatr, Vol 20 (No 2); Junr 2010
- 10) Peyman Eshghi, Hassan Abolghasemi. Selection Bias in reporting the prevalence of Transfusion Transmitted Infection Diseases in Iranian Hemophiliacs. Iranian Journal of Pathology(2009)4 (4).197-198
- 11) A. Zadeh-Vakili, **P. Eshghi**, Gh. Rastegar Lari<sup>2</sup>. Efficiency of *BclI* Restriction Fragment Length Polymorphism for Detection of Hemophilia A Carriers in Sistan and Baluchestan Province, Southeast of Iran. *Iran J Med Sci* March 2008; Vol 33 No 1 33
- 12) **P. Eshghi**. Complications of Combined Treatment with Deferiprone and Desferrioxamine in Thalassaemic Patients, *Iran J Med Sci*, 2007; 32(1)

## Researches; Scientific projects and Dissertations:

### International Multicentre Studies (As Main Investigator in IRAN):

- 1- **(3WINTERS-IPS):Type 3 Von Willebrand International Registries Inhibitor Prospective Study - Prospective, Multicentre, International, Non-interventional 5-year Clinical Study .Promoted by AB BONOMI Foundation, a NO-profit Organization with funds obtained from unrestricted grants of Five Companies-in process**

- 2- SIPPET( Survey of Inhibitors in Plasma-Product Exposed Toddlers) Study, and independent ,multicentre, international ,prospective ,controlled ,randomized,open labeled clinical trial.Promoted by Fondazione Angelo Bianchi Bonomi in more than 60 centers around the world –in process
- 3- SMART-7: Prospective Observational Study on NovoSeven® RoomTemperature Stable (VII25) in Patients with Haemophilia A or B.an international study. Promoted and sponsored by Novo Nordisk Company
- 4- TARGET: study:An observational sTudy to Assess the feasibility of combining data from patient ReGistries in countries with developing health care systems to EvaluaTe Haemophilia management. Promoted and sponsored by Novo Nordisk Company

#### National and multicenter projects and clinical trials as the Main Researcher

(ordered ,supervised or Granted by Ministry of Health of IRAN)

1. National Registry of congenital bleeding disorders In Iran. National project ,ordered and supervised by MOH(finished)
2. Randomized triple-blind controlled trial: Urine Iron excretion following Desfonak vs. Desferal administration in major thalassemic patients: A Multicenteric randomized triple-blind controlled clinical study (finished and going to be published)
3. Health Technology assessment of Implementation of Immune Tolerance Induction in hemophilia A patients with high titer inhibitor in Iran: a HTA study under supervision of National Health Research Institute).(finished and published)
4. Comparative cross over Triple blind Clinical Trial on safety and efficacy between Iranian produced Recombinant Factor Eight and Plasma derived Factor Eight inprevious treated hemphilac patients in Iran (finished)

5. **Efficacy and safety of Osveral® (Deferasirox) in Iranian major Thalassemic Patients with transfusional iron overload: :A One year Prospective Multicentric Open-Label Non-Comparative stud).**(finished and published)

Updated at 1-11-2018

A handwritten signature in blue ink, appearing to read 'Estghi', is centered on the page. The signature is written in a cursive style with a large initial 'E'.